Hua Medicine (华领医药) IPO: Little Upside to Fair Value
Hua Medicine launched the institutional book building today and intends to raise USD 111 to USD 124 million, with an implied market capitalization...
585 Views
Last Week in GER Research: Haidilao, Xiaomi, Ping An, 111, Qutoutiao, Nio and Tesla
Below is a recap of the key IPO and fundamental research produced by the Global Equity Research team. This week we highlight a differentiated...
460 Views
Last Week in GER Research: Tesla, Pinduoduo, Beigene, Koolearn, Pintec, STX and China Tower
Below is a recap of the key research produced by the Global Equity Research team. This week we highlight some detailed math on a potential Tesla...
455 Views
BeiGene (6160 HK): On a Stronger Post-Listing Footing than Ascletis
Hong Kong investors have had their first taste of biotech stocks with the recent listings of Ascletis Pharma Inc (1672 HK) and BeiGene Ltd (6160...
556 Views
BeiGene (百济神州) Post-IPO: An ADR Tracker with Limited Near-Term Upside
BeiGene is the second biotech company to list in Hong Kong under amended listing rules that allow biotech companies which are yet to see a profit...
538 Views